{
  "symbol": "MRNA",
  "name": "Moderna",
  "sector": "Health Care",
  "industry": "Biotechnology",
  "date_added": "2021-07-21",
  "headquarters": "Cambridge, Massachusetts",
  "founded": "2010",
  "market_cap": 12468.562944,
  "pe_ratio": null,
  "forward_pe": -3.7057474,
  "eps": -8.73,
  "revenue": 3176.999936,
  "profit_margin": -1.05666,
  "debt_to_equity": 7.401,
  "return_on_equity": -0.29341,
  "dividend_yield": null,
  "current_price": 32.2400016784668,
  "year_high": 129.38999938964844,
  "year_low": 23.149999618530273,
  "price_change_1d": -0.9219398543943929,
  "price_change_1w": 12.373653113721653,
  "price_change_1m": 23.430324052826546,
  "description": "Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and met",
  "website": "https://www.modernatx.com",
  "employees": 5800,
  "exchange": "NMS",
  "currency": "USD",
  "analyst_target_price": 47.59091,
  "recommendation": 2.84615,
  "number_of_analysts": 22,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 198.0,
    "target_low": 20.0,
    "target_mean": 47.59091,
    "target_median": 31.5
  },
  "last_updated": "2025-07-09T11:25:51.090080",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}